81 related articles for article (PubMed ID: 20687795)
21. Promising therapies for the treatment of chronic lymphocytic leukemia.
Morabito F; Recchia AG; Vigna E; De Stefano L; Bossio S; Morabito L; Pellicanò M; Palummo A; Storino F; Caruso N; Gentile M
Expert Opin Investig Drugs; 2015 Jun; 24(6):795-807. PubMed ID: 25728009
[TBL] [Abstract][Full Text] [Related]
22. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
23. [Chronic lymphocytic leukemia].
Aoki S
Rinsho Ketsueki; 2016 Mar; 57(3):238-48. PubMed ID: 27076234
[TBL] [Abstract][Full Text] [Related]
24. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?
Strati P; Caligaris-Cappio F
Curr Opin Oncol; 2011 Sep; 23(5):455-60. PubMed ID: 21681094
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic insights into the antileukemic activity of hyperforin.
Billard C; Merhi F; Bauvois B
Curr Cancer Drug Targets; 2013 Jan; 13(1):1-10. PubMed ID: 22924417
[TBL] [Abstract][Full Text] [Related]
26. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.
Willimott S; Baou M; Naresh K; Wagner SD
Br J Haematol; 2007 Sep; 138(6):721-32. PubMed ID: 17760804
[TBL] [Abstract][Full Text] [Related]
27. PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.
Plate JM
Leuk Lymphoma; 2004 Aug; 45(8):1519-29. PubMed ID: 15370202
[TBL] [Abstract][Full Text] [Related]
28. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.
Cuní S; Pérez-Aciego P; Pérez-Chacón G; Vargas JA; Sánchez A; Martín-Saavedra FM; Ballester S; García-Marco J; Jordá J; Durántez A
Leukemia; 2004 Aug; 18(8):1391-400. PubMed ID: 15175625
[TBL] [Abstract][Full Text] [Related]
29. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
Hegde GV; Peterson KJ; Emanuel K; Mittal AK; Joshi AD; Dickinson JD; Kollessery GJ; Bociek RG; Bierman P; Vose JM; Weisenburger DD; Joshi SS
Mol Cancer Res; 2008 Dec; 6(12):1928-36. PubMed ID: 19074837
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.
Bailón E; Ugarte-Berzal E; Amigo-Jiménez I; Van den Steen P; Opdenakker G; García-Marco JA; García-Pardo A
J Leukoc Biol; 2014 Aug; 96(2):185-99. PubMed ID: 25080557
[TBL] [Abstract][Full Text] [Related]
31. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
32. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Giannoni P; Cutrona G; Totero D
Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
[TBL] [Abstract][Full Text] [Related]
33. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
Thomas A; Pepper C; Hoy T; Bentley P
Leuk Lymphoma; 2004 May; 45(5):997-1008. PubMed ID: 15291360
[TBL] [Abstract][Full Text] [Related]
34. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
[TBL] [Abstract][Full Text] [Related]
35. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
[TBL] [Abstract][Full Text] [Related]
36. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Crassini K; Stevenson WS; Mulligan SP; Best OG
Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
[TBL] [Abstract][Full Text] [Related]
37. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy for chronic lymphocytic leukemia: current status and future directions.
Arnason JE; Brown JR
Drugs; 2015 Feb; 75(2):143-55. PubMed ID: 25619739
[TBL] [Abstract][Full Text] [Related]
39. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
40. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]